Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

JAK2 V617F mutation, multiple hematologic and non-hematologic processes: an association?

Liu KG, Verma A, Derman O, Kornblum N, Janakiram M, Braunschweig I, Battini R.

Biomark Res. 2016 Oct 19;4:19. eCollection 2016.

2.

Adult T-cell leukemia/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy.

Zell M, Assal A, Derman O, Kornblum N, Battini R, Wang Y, Narasimhulu DM, Mantzaris I, Shastri A, Verma A, Ye H, Braunschweig I, Janakiram M.

Oncotarget. 2016 Aug 9;7(32):51981-51990. doi: 10.18632/oncotarget.10223.

3.

High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort.

Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A, Mantzaris I, Janakiram M, Battini R, Kornblum N, Derman O, Gritsman K, Al-Hafidh J, Wang Y, Halmos B, Steidl U, Maciejewski JP, Braunschweig I, Verma A.

Leukemia. 2016 Aug;30(8):1793-5. doi: 10.1038/leu.2016.74. Epub 2016 Apr 29. No abstract available.

PMID:
27125205
4.

Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.

Flowers CR, Costa LJ, Pasquini MC, Le-Rademacher J, Lill M, Shore TB, Vaughan W, Craig M, Freytes CO, Shea TC, Horwitz ME, Fay JW, Mineishi S, Rondelli D, Mason J, Braunschweig I, Ai W, Yeh RF, Rodriguez TE, Flinn I, Comeau T, Yeager AM, Pulsipher MA, Bence-Bruckler I, Laneuville P, Bierman P, Chen AI, Kato K, Wang Y, Xu C, Smith AJ, Waller EK.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1197-205. doi: 10.1016/j.bbmt.2016.03.018. Epub 2016 Mar 31.

5.

Analysis of chronic myelogenous leukemia in an underserved, inner-city cohort shows a significant five year overall survival that is not affected by choice of tyrosine kinase inhibitor.

Assal A, Dong B, Khan H, Medavarapu R, Shastri A, Pradhan K, Friedman E, Mantzaris I, Janakiram M, Battini R, Kornblum N, Yu Y, Verma A, Braunschweig I, Derman O.

Leuk Lymphoma. 2016 Oct;57(10):2452-5. doi: 10.3109/10428194.2016.1142087. Epub 2016 Feb 17. No abstract available.

PMID:
26886689
6.

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators..

Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5.

PMID:
26671818
7.

Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.

Tamari R, Schinke C, Bhagat T, Roth M, Braunschweig I, Will B, Steidl U, Verma A.

Leuk Lymphoma. 2014 Dec;55(12):2901-6. doi: 10.3109/10428194.2014.894186. Epub 2014 Mar 20.

PMID:
24650011
8.

Unreported use of an herbal supplement resulting in decreased clearance of intravenous busulfan in a patient undergoing auto-SCT.

Carter J, Yeh RF, Braunschweig I, Barta SK.

Bone Marrow Transplant. 2014 Feb;49(2):313-4. doi: 10.1038/bmt.2013.169. Epub 2013 Nov 4. No abstract available.

PMID:
24185586
9.

CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation.

Marty FM, Winston DJ, Rowley SD, Vance E, Papanicolaou GA, Mullane KM, Brundage TM, Robertson AT, Godkin S, Momméja-Marin H, Boeckh M; CMX001-201 Clinical Study Group..

N Engl J Med. 2013 Sep 26;369(13):1227-36. doi: 10.1056/NEJMoa1303688.

10.

Signal transduction inhibitors in treatment of myelodysplastic syndromes.

Bachegowda L, Gligich O, Mantzaris I, Schinke C, Wyville D, Carrillo T, Braunschweig I, Steidl U, Verma A.

J Hematol Oncol. 2013 Jul 10;6:50. doi: 10.1186/1756-8722-6-50. Review.

11.

Linked-in: design and efficacy of antibody drug conjugates in oncology.

Feld J, Barta SK, Schinke C, Braunschweig I, Zhou Y, Verma AK.

Oncotarget. 2013 Mar;4(3):397-412.

12.

Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma.

Leshchenko VV, Kuo PY, Shaknovich R, Yang DT, Gellen T, Petrich A, Yu Y, Remache Y, Weniger MA, Rafiq S, Suh KS, Goy A, Wilson W, Verma A, Braunschweig I, Muthusamy N, Kahl BS, Byrd JC, Wiestner A, Melnick A, Parekh S.

Blood. 2010 Aug 19;116(7):1025-34. doi: 10.1182/blood-2009-12-257485. Epub 2010 Apr 28.

13.

Eosinophilic variant of chronic myeloid leukemia with vascular complications.

Gotlib V, Darji J, Bloomfield K, Chadburn A, Patel A, Braunschweig I.

Leuk Lymphoma. 2003 Sep;44(9):1609-13. Review.

PMID:
14565666
14.

High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer.

Braunschweig I, Mirza NQ, Rondon G, Lauppe J, Mehra R, Gajewski J, Körbling M, Huh YO, Geisler D, Gee AP, Champlin R, Przepiorka D.

Cytotherapy. 2000;2(2):105-10.

PMID:
12042047
15.

Chronic graft-versus-host disease after allogeneic blood stem cell transplantation.

Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I, Huh YO, Giralt S, Braunschweig I, van Besien K, Champlin R.

Blood. 2001 Sep 15;98(6):1695-700.

16.

Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.

Bibawi S, Abi-Said D, Fayad L, Anderlini P, Ueno NT, Mehra R, Khouri I, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Andreeff M, Andersson BS, Estey EH, Champlin R, Przepiorka D.

Am J Hematol. 2001 Aug;67(4):227-33.

17.

Dendritic cell-mediated stimulation of the in vitro lymphocyte response to Aspergillus.

Grazziutti M, Przepiorka D, Rex JH, Braunschweig I, Vadhan-Raj S, Savary CA.

Bone Marrow Transplant. 2001 Mar;27(6):647-52.

18.

Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy.

Sarris AH, Braunschweig I, Medeiros LJ, Duvic M, Ha CS, Rodriguez MA, Hagemeister FB, McLaughlin P, Romaguera J, Cox J, Cabanillas F.

J Clin Oncol. 2001 Jan 15;19(2):398-405.

PMID:
11208831
19.

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.

Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno NT, Molldrem J, Champlin R.

Blood. 2001 Feb 1;97(3):631-7.

20.

Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1.

Przepiorka D, Saliba R, Cleary K, Fischer H, Tonai R, Fritsche H, Khouri IF, Folloder J, Ueno NT, Mehra R, Ippoliti C, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Anderlini P, Andersson BS, Champlin R.

Biol Blood Marrow Transplant. 2000;6(2A):190-7.

PMID:
10816027

Supplemental Content

Loading ...
Support Center